Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Tasly Pharmaceutical Group Co has a current ratio of 3.72. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Tasly Pharmaceutical Group Co's Current Ratio or its related term are showing as below:
SHSE:600535'
s Current Ratio Range Over the Past 10 Years
Min: 1.24 Med: 2.98 Max: 6.19
Current: 3.72
During the past 13 years, Tasly Pharmaceutical Group Co's highest Current Ratio was 6.19. The lowest was 1.24. And the median was 2.98.
SHSE:600535's Current Ratio is ranked better than 75.3% of 1000
companies
in the Drug Manufacturers industry
Industry Median: 2
vs SHSE:600535: 3.72
Tasly Pharmaceutical Group Co (SHSE:600535) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Tasly Pharmaceutical Group Co Current Ratio Related Terms
Tasly Pharmaceutical Group Co Current Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SHSE:600535 vs ZTS, UTHR: Current Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Tasly Pharmaceutical Group Co's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Tasly Pharmaceutical Group Co Current Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Tasly Pharmaceutical Group Co's Current Ratio distribution charts can be found below:
* The bar in red indicates where Tasly Pharmaceutical Group Co's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Tasly Pharmaceutical Group Co (SHSE:600535) has a Current Ratio of 3.72 as of Mar. 2026. This is 25% above median its historical median of 2.98. Over the past decade, Tasly Pharmaceutical Group Co's Current Ratio has ranged from 1.24 to 6.19. According to the industry distribution chart, Tasly Pharmaceutical Group Co ranks #247 out of 1000 companies in the Drug Manufacturers industry, placing it in the top 24.7%.
Is Tasly Pharmaceutical Group Co's Current Ratio too high?
Tasly Pharmaceutical Group Co's current Current Ratio of 3.72 is 25% above median its 10-year median of 2.98. Over the past 10 years, this metric has ranged from a low of 1.24 to a high of 6.19. The Drug Manufacturers industry median Current Ratio is 2.00. Tasly Pharmaceutical Group Co's value of 3.72 is 86% above this industry median. Based on the distribution chart, Tasly Pharmaceutical Group Co ranks #247 out of 1000 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Tasly Pharmaceutical Group Co has a GF Score™ of 79/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Tasly Pharmaceutical Group Co's Current Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Tasly Pharmaceutical Group Co ranks #247 out of 1000 companies for Current Ratio. This places Tasly Pharmaceutical Group Co in the top 25% of its industry — outperforming the majority of peers. The industry median Current Ratio is 2.00. Tasly Pharmaceutical Group Co's value of 3.72 is 86% above this benchmark. Historically, Tasly Pharmaceutical Group Co's own Current Ratio has ranged from 1.24 to 6.19 over the past decade. While the company's 10-year median is 2.98 vs. the industry median of 2.00, Tasly Pharmaceutical Group Co has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Drug Manufacturers company?
The median Current Ratio among Drug Manufacturers companies is 2.00, based on 1,000 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Tasly Pharmaceutical Group Co's current Current Ratio of 3.72 is 86% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median Current Ratio is 2.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Tasly Pharmaceutical Group Co's current Current Ratio is 3.72, which is 25% above median its own 10-year median of 2.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Tasly Pharmaceutical Group Co stock overvalued right now?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co (SHSE:600535) is currently considered Fairly Valued. The stock's GF Value™ is ¥15.06, compared to a current price of ¥14.59 — trading 3.1% below its estimated fair value. The current Current Ratio is 3.72, which is 25% above median its 10-year median of 2.98 and 86% above the Drug Manufacturers industry median of 2.00. Tasly Pharmaceutical Group Co's overall GF Score™ is 79/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Tasly Pharmaceutical Group Co (SHSE:600535), the current Current Ratio is 3.72 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Tasly Pharmaceutical Group Co (SHSE:600535) Overvalued in 2026?
Based on GuruFocus' analysis, Tasly Pharmaceutical Group Co stock appears to be undervalued.
The current stock price of ¥14.59 is trading 3.1% below its estimated GF Value™ of ¥15.06.
GuruFocus considers Tasly Pharmaceutical Group Co to be Fairly Valued.
Key valuation signals for SHSE:600535:
Current Ratio: 3.72 (25% above median its 10-year median of 2.98)
GF Value™: ¥15.06 vs. price of ¥14.59 (3.1% below fair value)
Industry Position: 86% above the Drug Manufacturers median (#247 of 1000)
No single metric tells the full story. See the SHSE:600535 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Tasly Pharmaceutical Group Co Business Description
Tasly Pharmaceutical Group Co Ltd is a China-based company engaged in the manufacturing and distribution of pharmaceutical products. Its herbal medicines include Tasly Cerebral Care Granules and Tasly ICP. Its chemical medicines comprise of Ketotifen Fumarate Tablets, Thiamphenicol Capsules, Glucurolactone Tablets and Sulpiride Tablets. Some of the other products offered by the company include PharmceuticalSubstances & API, HerbalExtract, and Concentrated Herbal Granules.
79GF Score
Get the complete analysis for SHSE:600535
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SHSE:600535 has been successfully added to your 
